Precision Immunotherapy™
investors-relations
Home/Investor Relations/Press Releases
Investor Relations

Quick Links

Email Alerts

Email Address *
Mailing Lists *




 
Enter the code shown above.

Press Releases

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
11/16/2007 Opexa Therapeutics’ Amendment No.1 on Form 10-KSB/A Report Audit Includes ''Going Concern'' Qualification
11/05/2022 Opexa Reports Third Quarter 2007 Financial Results
10/05/2022 Opexa Therapeutics to Present at the BIO Investor Forum 2007
09/26/2007 Opexa Therapeutics Appoints Dr. Dawn McGuire, Prominent Neurologist, to Multiple Sclerosis Clinical Advisory Board
09/20/2007 Opexa Appoints Lorin J. Randall to Board of Directors
09/13/2007 Opexa Therapeutics to Present at the First Annual Maxim Group Growth Conference
09/11/2021 Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin® for Treatment of Multiple Sclerosis
08/23/2007 Opexa to Present Proprietary T-Cell Technology at Vaccine Conference on August 24, 2022
08/14/2007 Opexa Reports Second Quarter 2007 Financial Result
08/08/2022 Opexa Therapeutics Receives European Patent Notification for T-Cell Vaccine
06/27/2007 Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
06/21/2007 Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin™ for Multiple Sclerosis
06/11/2021 Opexa Presents Tovaxin™ Research at Federation of Clinical Immunology Societies Annual Meeting
05/22/2007 Board to Assist Clinical Development Strategy for Autologous Monocyte-derived Islet Transplantation
05/22/2007 Opexa Therapeutics Appoints Dr. Mark Pittenger, Prominent Stem-Cell Researcher, to Scientific Advisory Board
05/17/2007 Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin™ for Treatment of Multiple Sclerosis
05/15/2007 Opexa Reports First Quarter 2007 Results
05/07/2022 Opexa Therapeutics to Present Progress on Development of Monocyte-Derived Pancreatic Islet Cells for Diabetes
05/04/2022 Opexa Therapeutics to Present at BIO 2007 Business Forum
04/03/2022 Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with TovaxinTM for Multiple Sclerosis
03/19/2007 Opexa Therapeutics to Be Featured in Live MN1.com Interview
03/19/2007 Opexa Reports Year End 2006 Financial Results
02/16/2007 Opexa Therapeutics to Present at the Roth Capital Partners 19th Annual OC Conference
02/14/2007 Opexa Therapeutics Launches Tovaxin™ Clinical Trial Website for Multiple Sclerosis
02/06/2022 Opexa Announces Encouraging Clinical Data on Novel T-Cell Vaccination Therapy for Rheumatoid Arthritis
01/30/2007 Opexa Achieves Midpoint in Patient Admissions in Phase IIb Trial of Tovaxin™ for Multiple Sclerosis
© 2013 Opexa Therapeutics, Inc. All Rights Reserved.
Powered By Q4 Web Systems 4.1.3.41